Results 41 to 50 of about 32,738 (290)

Primary ovarian high-grade endometrial stromal sarcoma: a case report

Journal of Medical Case Reports, 2021
Background Primary ovarian high-grade endometrial stromal sarcoma is a very rare disease. Even though it has poor prognosis, the gold standard treatment has not been established owing to its rarity.
Ji Sun Lee, Dayong Lee, Jisun Lee, Man-Hoon Han, Dae Gy Hong, Hyun Jung Lee   +5 more
doaj   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer [PDF]

, 2017
Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical,
Biacchi, Daniele, Christopoulou, Athina, Ciardi, Antonio, Cornali, Tommaso, Efstathiou, Elias, Framarino dei Malatesta, Marialuisa, Kopanakis, Nikolaos, Sammartino, Paolo, Spagnoli, Alessandra, Spiliotis, John   +9 more
core   +1 more source

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim, De Wever, Olivier, Descamps, Benedicte, Gremonprez, Félix, Izmer, Andrei, Vanhaecke, Frank, Vanhove, Christian   +6 more
core   +4 more sources

Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.

JAMA Surgery, 2021
Importance To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM ...
K. Rovers, C. Bakkers, S. Nienhuijs, J. Burger, G. Creemers, A. M. Thijs, A. Brandt-Kerkhof, E. Madsen, E. van Meerten, J. Tuynman, M. Kusters, K. Versteeg, A. Aalbers, N. Kok, T. Buffart, M. Wiezer, D. Boerma, M. Los, P. D. de Reuver, A. Bremers, H. Verheul, S. Kruijff, D. D. de Groot, A. Witkamp, W. V. van Grevenstein, M. Koopman, J. Nederend, M. Lahaye, O. Kranenburg, R. Fijneman, I. van ’t Erve, P. Snaebjornsson, P. Hemmer, M. Dijkgraaf, C. Punt, P. Tanis, I. D. de Hingh   +36 more
semanticscholar   +1 more source

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of ‘Italian Peritoneal Surface Malignancies Oncoteam—S.I.C.O.’

Annals of Surgical Oncology, 2021
The development of multimodality treatment, including cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC), has led to promising results in selected patients with peritoneal disease of gastric origin.
L. Marano, D. Marrelli, P. Sammartino, D. Biacchi, L. Graziosi, E. Marino, F. Coccolini, P. Fugazzola, M. Valle, O. Federici, D. Baratti, M. Deraco, A. di Giorgio, A. Macrì, E. Pasqual, M. Framarini, M. Vaira, F. Roviello   +17 more
semanticscholar   +1 more source

Effect of Intraperitoneal Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy

Technology in Cancer Research & Treatment, 2023
Despite extensive treatment with surgery and chemotherapy many patients with peritoneal metastases from colorectal cancer experience intraperitoneal disease relapse. The α-emitting 224 radium-labelled microparticle radionuclide therapeutic Radspherin® is
Ebbe Billmann Thorgersen MD, PhD, Jørund Asvall MD, Camilla Schjalm MSc, Karin Ekholt McAdam MSc, Øyvind Sverre Bruland MD, PhD, Stein Gunnar Larsen MD, PhD, Tom Eirik Mollnes MD, PhD   +6 more
doaj   +1 more source

Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]

, 2015
BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio, Biacchi, Daniele, Cardi, Maurizio, DI GIORGIO, Angelo, Mingarelli, Valentina, Musio, Daniela, Sammartino, Paolo, Sibio, Simone, Sollazzo, BIANCA MARIA   +8 more
core   +2 more sources

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers

International Journal of Molecular Sciences, 2022
Most patients with epithelial ovarian cancers (EOCs) are at advanced stages (stage III–IV), for which the recurrence rate is high and the 5-year survival rate is low.
Pei-Qi Lim, I. Han, K. Seow, Kuo-Hu Chen
semanticscholar   +1 more source

Perception, knowledge and protective practices for surgical staff handling antineoplastic drugs during HIPEC and PIPAC

Pleura and Peritoneum, 2022
Two surgical techniques used for peritoneal metastasis involve a risk of exposure to antineoplastic drugs (ADs): hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Benoist Hubert, Eveno Clarisse, Wilson Sarah, Vigneron Nicolas, Guilloit Jean-Marc, Morello Rémy, Simon Nicolas, Odou Pascal, Saint-Lorant Guillaume   +8 more
doaj   +1 more source